LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

599.45 -0.56

Buy Sell

Overview

Share price change

24h

Current

Min

595.49

Max

602.15

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
EPS	-4.956
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+3.62% upside

Market Stats
By TradingEconomics
Market Cap	4.5B 14B
Previous open	600.01
Previous close	599.45

News Sentiment

By Acuity

50%

157 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 gru 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26 gru 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 gru 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 gru 2025, 19:24 UTC

Acquisitions, Mergers, Takeovers

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 gru 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 gru 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26 gru 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 gru 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 gru 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 gru 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 gru 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 gru 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 gru 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26 gru 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 gru 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 gru 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 gru 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 gru 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 gru 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 gru 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 gru 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 gru 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 gru 2025, 00:20 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 gru 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 gru 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 gru 2025, 19:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

24 gru 2025, 19:09 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 gru 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

3.62% upside

12 Months Forecast

Average 624.67 USD 3.62%

High 900 USD

Low 527 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

157 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.